Transaction value based on SEC Form 4 weighted average purchase price ($27.06); post-transaction value based on June 18, 2026 market close ($25.85). Develops cell-penetrating miniproteins (CPMPs) ...

Why Parabilis Medicines Stock Is On Investors’ Radar Parabilis Medicines (PBLS) has recently drawn fresh attention after a sharp single day move, with the stock closing at $27.26 and down around 10% ...

Parabilis Medicines (PBLS) had a thunderous debut on Nasdaq this week — opening at a little over $33, up an exciting 67% versus the $20 initial public offering (IPO) price. PBLS raised some $670 ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Parabilis Medicines, Inc. (PBLS) has filed to raise drug development funding via an IPO, according to an S-1 registration statement. The company is a clinical-stage biopharma developing helicon ...

Parabilis Medicines (PBLS) has filed for an upsized initial public offering in the U.S., seeking to raise more than $600M as the cancer drug developer backed by Regeneron (REGN) targets a valuation of ...

Parabilis Medicines, Inc. (PBLS) priced its initial public offering of 33.5 million shares at $20.00 per share, the company ...

Just a few days after a well-received initial public offering, a director of drug developer Parabilis Medicines (NASDAQ:PBLS) bought shares in the open market. Director Alan Sebulsky disclosed the ...